Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TNFAIP1

TNFAIP1

Basics

Aliases:
This biomarker is also known as:
  • Protein B12,
  • BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation,
  • EDP1,
  • B61,
  • tumor necrosis factor, alpha-induced protein 1,
  • B12,
  • OTTHUMP00000163324,
  • protein 2,
  • hBACURD2,
  • Tumor necrosis factor, alpha-induced protein 1, endothelial,
  • MGC2317,
  • Q13829,
  • BACURD2,
  • BTB/POZ domain-containing protein TNFAIP1,

View in BioMuta

Description…

The expression of this gene can be induced by the tumor necrosis factor alpha (TNF) in umbilical vein endothelial cells. Mouse studies suggest the expression of this gene is developmentally regulated in a tissue-specific manner. Thought to be involved in regulation of cytoskeleton structure.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

TNFAIP1 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. TNFAIP1 was not in the group of 13 selected for further validation.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html